Insights on the Global Drug Discovery Market Trends 2022 | Segmentation, Outlook, Industry Report to 2028

High-throughput screening determines the drug design of potential drugs. Therefore, segment growth is driven by increasing demand for new effective drugs to improve existing therapies and develop new therapies.

Scope of the Report

The research study analyzes the global Drug Discovery industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis

o Import and Export Overview

o Volume Analysis

o Current Market Trends and Future Outlook

o Market Opportunistic and Attractive Investment Segment

Market Segmentation:

By Drug Type

• Small Molecule Drugs
• Biologic Drugs

By Technology

• High Throughput Screening
• Pharmacogenomics
• Combinatorial Chemistry
• Nanotechnology
• Other Technologies

By End User

• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Other End Users

Company Profiles

• Genome Biologics
• Abbott Laboratories Inc.
• Agilent Technologies Inc.
• AstraZeneca PLC
• AVIVA Biosciences
• Bayer AG

Geographic Coverage

o North America Market Size and/or Volume

o Latin America Market Size and/or Volume

o Europe Market Size and/or Volume

o Asia-Pacific Market Size and/or Volume

o Rest of the world Market Size and/or Volume

Key Questions Answered by Drug Discovery Market Report

1. What was the Drug Discovery Market size in 2019 and 2020; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Drug Discovery Market during the forecast period (2022-2028)?

3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).

4. Which manufacturer/vendor/players in the Drug Discovery Market was the market leader in 2020?

5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.